Prot #CP-MGD006-01: A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Ri

Project: Research project

Project Details

StatusFinished
Effective start/end date7/5/19 → 7/5/22

Funding

  • Macrogenics, Inc. (Prot #CP-MGD006-01)